TECVAYLI® Monotherapy Shows Superior Survival vs Standard Care in Early Relapsed, Heavily Pretreated Myeloma

TECVAYLI® Monotherapy Shows Superior Survival vs. Standard Care in Early Relapsed, Heavily Pretreated Multiple Myeloma Johnson & Johnson, a worldwide leader in multiple myeloma therapies, today announced positive topline results…

Read MoreTECVAYLI® Monotherapy Shows Superior Survival vs Standard Care in Early Relapsed, Heavily Pretreated Myeloma

Biogen Secures European Commission Approval for High-Dose SPINRAZA® (nusinersen) Regimen in Spinal Muscular Atrophy

Biogen Secures European Commission Approval for High-Dose SPINRAZA® (nusinersen) Regimen in Spinal Muscular Atrophy Biogen Inc. today announced the European Commission (EC) has granted marketing authorization for a high dose…

Read MoreBiogen Secures European Commission Approval for High-Dose SPINRAZA® (nusinersen) Regimen in Spinal Muscular Atrophy